Gilead opts for $3,120 US insurer price for Covid-19 drug remdesivir — but some say it should be free
Gilead has rolled out its much-discussed price for remdesivir, and it’s ringing in well below the figures expected by some of the more aggressive Wall Street analysts.
Gilead CEO Daniel O’Day noted in an open letter Monday morning that it will charge governments around the globe $390 per vial — $2,340 for a 5-day course of the drug, which was quickly approved for Covid-19 after posting modest efficacy in a controlled study. For US insurers, which look for discounts, the cost will be $520 per vial, $3,120 in total for the full course. And he quickly moved to defend the price tag in an open letter.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.